Rituxan Hycela® (rituximab and hyaluronidase human)
for Leukemia

Rituxan Hycela combines rituximab, a targeted cancer drug that interferes with cancer cell growth, and hyaluronidase, a genetically engineered enzyme that temporarily breaks down hyaluronic acid, improving rituximab absorption under the skin. It treats follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia, offering patients more convenient and effective therapy.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Leukemia